drugset / Trial / NCT02616965
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Phase 1
Completed
16 enrolled
Fox Chase Cancer Center
Celgene Corporation · collabSeagen Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I Trial to assess the feasibility of Romidepsin combined with Brentuximab Vedotin for patients requiring Systemic Therapy for Cutaneous T-cell Lymphoma.
Timeline
- Start
- 2017-02-22
- Primary completion
- 2022-08-08
- Completion
- 2024-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 0.9 mg/kg | — |
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.2 mg/kg | — |
| Subject | Romidepsin | Peptide | 10 mg/m2 | — |
| Subject | Romidepsin | Peptide | 14 mg/m2 | — |